Skip to main content
. 2012 Jun;56(6):2941–2947. doi: 10.1128/AAC.00338-12

Fig 1.

Fig 1

Flow diagram of a randomized trial comparing a switch to an entecavir (ETV)-plus-adefovir (ADV) combination with continuation of lamivudine (LAM)-plus-ADV combination therapy in LAM-resistant chronic hepatitis B patients with suboptimal response to LAM-plus-ADV combination therapy.